Although some studies have shown that HGF/MET pathway might be implicated in B-cell neoplasms particularly diffuse large B-cell lymphoma (DLBL) and multiple myeloma (MM) [11-18], it is still an unresolved issue for the impact of MET CNA in the survival of patients with these hematological malignancies. This evidence concerns the gene MET and hematologic disorder.